title: The Olivieri case: lessons for Australasia.
abstract: The case of Dr. Nancy Olivieri, the Hospital for Sick Children, the University of Toronto, and Apotex Inc. vividly illustrates many of the issues central to contemporary health research and the safety of research participants. First, it exemplifies the financial and health stakes in such research. Second, it shows deficits in the ways in which research is governed. Finally, it was and remains relevant not only in Toronto but in communities across Canada and well beyond its borders because, absent appropriate policies, what happened in Toronto could have happened (and could well still happen) elsewhere. In Part One of this paper, we review the facts of the Olivieri case relevant to the issues we wish to highlight: first, the right of participants in a clinical trial to be informed of a risk that an investigator had identified during the course of the trial and the obligation of the investigator to inform participants (both her own and those of other investigators); and second, the obligation of institutions to protect and promote the well-being of research participants as well as academic freedom and research integrity, the obligations of research sponsors to inform participants, research regulators, and others about unforeseen risks, and the obligations of research regulators to ensure that participants are informed of unforeseen risks and to otherwise protect and promote research integrity. In Part Two, we relate these facts and issues to New Zealand and Australia. We also make detailed recommendations for changes to the various instruments used for the governance of research involving humans in Australasia.
authors.affiliation: Dalhousie University, Canada.
authors.forename: Jocelyn
authors.initials: J
authors.lastname: Downie
authors.forename: Jon
authors.initials: J
authors.lastname: Thompson
authors.forename: Patricia
authors.initials: P
authors.lastname: Baird
authors.forename: Susan
authors.initials: S
authors.lastname: Dodds
mesh_terms: D001315:Australia; D035843:Biomedical Research / Q000941:ethics* / Q000592:standards*; D002170:Canada; D002986:Clinical Trials as Topic / Q000941:ethics* / Q000592:standards*; D003219:Confidentiality / Q000941:ethics; D016265:Conflict of Interest; D000077543:Deferiprone; D030881:Disclosure / Q000941:ethics* / Q000592:standards*; D004345:Drug Industry / Q000941:ethics; D017408:Guidelines as Topic; D006801:Humans; D007258:Informed Consent / Q000941:ethics* / Q000592:standards*; D007373:Interinstitutional Relations; D009520:New Zealand; D011728:Pyridones / Q000009:adverse effects; D035842:Research Subjects; D012109:Research Support as Topic / Q000941:ethics*; D012306:Risk; D014495:Universities / Q000941:ethics
chemical_list: D011728:Pyridones; D000077543:Deferiprone